Despite a decline in the incidence of squamous cell carcinomas (SCCs) over the past 20 years, their survival rate has remained nearly the same, indicating that treatment options have not improved relative to other cancer types. Immunotherapies have a high potential for a sustained effect in SCC patients, but their response rate is low. Here, we review the suppressive role of transforming growth factor‐beta (TGFβ) on the antitumor immune response in SCC and present its potential as a therapeutic target in combination with the current range of immunotherapies available for SCC patients. We conclude that SCCs are an optimal cancer type to study the effectiveness of TGFβ inhibition due to the prevalence of dysregulated TGFβ signaling in them.

中文翻译：

---

转化生长因子-β在鳞状细胞癌的免疫抑制和慢性炎症中的作用。

尽管在过去的20年中鳞状细胞癌（SCC）的发病率有所下降，但它们的存活率几乎保持不变，这表明相对于其他癌症类型，治疗选择没有改善。免疫疗法在SCC患者中具有持续疗效的潜力很高，但其缓解率很低。在这里，我们回顾了转化生长因子-β（TGFβ）对SCC抗肿瘤免疫反应的抑制作用，并结合目前可用于SCC的免疫疗法范围，介绍了其作为治疗靶标的潜力。我们得出的结论是，由于SCC中普遍存在失调的TGFβ信号传导，因此是研究TGFβ抑制效果的最佳癌症类型。